• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Curie-Cancer, Inventiva partners in epigenetics for cancer

Curie-Cancer, Inventiva partners in epigenetics for cancer

September 17, 2014
CenterWatch Staff

Curie-Cancer, the body responsible for Institut Curie’s industry partnership activities, and Inventiva, a French drug discovery company focusing on therapeutic approaches involving transcription factors and epigenetic targets, have launched the Epicure project, which just has received financial backing from France’s national research agency, the ANR (Agence Nationale pour la Recherche).

The Epicure project focuses on two novel epigenetic targets implicated in immunomodulation. It aims to confirm their therapeutic potential for the treatment of cancers such as breast cancer, ovarian cancer and melanoma, as well as some respiratory diseases. It also aims to identify molecules that are capable of regulating the activity of the targets and are therefore likely to become active drugs for the treatment of these diseases. The funding provided by the ANR covers a period of four years.

The Epicure project will involve three teams from the Institut Curie: the Epigenetics team led by Geneviève Almouzni, director of research at the French national center for scientific research the CNRS (Center national de recherche scientifique) and director of the research center at the Institut Curie; the Immunology team headed by Sebastian Amigorena, director of research at the CNRS; and Sergio Roman-Roman’s translational research team. Inventiva’s epigenetics drug discovery team will join and partner with Curie teams.

The purpose of the Epicure project is to produce novel molecules that modulate the epigenetic targets under evaluation. These would be ready to go into clinical development upon completion of the project. Its ultimate goal is to find new drugs that will activate immune responses against cancer cells.  

“The ANR funding provides additional resources for the partnership we have established with the Institut Curie. It adds to our portfolio of epigenetic programs, which aims to confirm novel epigenetic mechanisms and develop innovative drugs to treat cancer,” said Pierre Broqua, co-founder and scientific director of Inventiva. “By combining our expertise in target validation and drug discovery with the Institut Curie's skills in basic and translational oncology research, we can achieve rapid and significant outcomes for patients.”

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing